SANTA ROSA, Calif. – May 7, 2015 – Direct Flow Medical®, Inc., an innovative structural heart company, has named Daniel Lemaitre as President and Chief Executive Officer (CEO), and David Boyle as Chief Financial Officer (CFO), effective immediately. The moves come as the Company enjoys encouraging commercial uptake of its transcatheter aortic heart valve system in Europe, and continues enrollment in SALUS, its pivotal study in the United States. Current CEO Bernard Lyons will be retiring from the company.

Lemaitre previously served as President and CEO of CoreValve from 2008 to 2009, where he helped orchestrate the European launch of the company’s transcatheter heart valve and the company’s eventual $800 million acquisition by Medtronic. Prior to that, he was a Senior Vice President for Medtronic, where he led strategic planning and business development. Earlier in his career, Lemaitre was considered one of the top-ranked medical device analysts in the country, leading Cowen & Company’s healthcare research team, and then Merrill Lynch’s medical technology team. He currently serves as Chairman of privately-held Bioventus and is on the board of Endologix (lead director) and Globus Medical.

David Boyle has served as CFO for five healthcare companies over the course of his 32-year financial career, most recently for Ogenx Therapeutics, an emerging company focused on pro-drugs for a variety of diseases. The public companies where he has served as CFO include Bionovo, AVI BioPharma, where he also served as interim CEO, XOMA and Salix Pharmaceuticals. His experience includes initial public offerings, closing of significant new private funding and government contracts, and implementation of new financial and accounting systems. Earlier in his career, Boyle had extensive international and merger and acquisitions experience with Ernst & Young and the Ares Serono Group.

“Dan is the ideal person to help Direct Flow Medical realize its mission of becoming a true structural heart leader,” said Paul LaViolette, Chairman of the Board for Direct Flow Medical. “Dan’s knowledge of the aortic valve space and the medical device landscape as a whole is unparalleled. His experience will be extraordinarily valuable as we become a major participant in the market. In addition, David Boyle will provide Dan with exceptionally strong financial stewardship as we build the company in the years ahead.”

“Direct Flow Medical has an innovative platform technology addressing one of the largest and fastest-growing markets in medical technology today – transcatheter aortic heart valve replacement, or TAVR – with the opportunity to address other structural heart diseases,” said Lemaitre. “I am impressed with the unique benefits of the Company’s technology platform and excited to be part of the team that will bring tremendous value to patients, physicians and investors.”

“As we make this transition, I want to thank Bernie Lyons for his instrumental leadership over the last nine years with the company,” said LaViolette. “He took an innovative idea and made it real, generating excellent clinical results, securing critical financing, building a robust commercial organization in Europe and achieving strong regulatory momentum in the U.S. He built this company into one with tremendous growth potential and we are grateful for his contribution.”

About Direct Flow Medical, Inc.

Founded in 2004, Direct Flow Medical, Inc. is focused on developing novel transcatheter heart valve technologies that improve patient outcomes while reducing complications. The company is headquartered in Santa Rosa, California, with technology and manufacturing facilities in Lake Forest, California. The company’s proprietary technology, initially aimed at aortic valve disease, is applicable to a broad range of structural heart diseases. Direct Flow Medical investors include EDF Ventures, New Leaf Venture Partners, Spray Venture Partners, Foundation Medical Partners, VantagePoint Venture Partners, ePlanet Venture Partners, SV Life Sciences and strategic corporate investors. For further information, please visit the Web site at




Chronic Communications



The Direct Flow Medical Transcatheter Aortic Valve System has not been approved for sale in the USA, Canada or Japan.

Direct Flow Medical and the Direct Flow logo are trademarks of Direct Flow Medical, Inc.


The information on this site is only intended for health care providers in certain markets outside the United States (US) where the Direct Flow Medical Trancatheter Aortic Valve Replacement System is approved for use as indicated by the instructions for use. The information on this page is not intended for health care providers in the US or US health care institutions as this site contains information about a product that is limited by US law to investigational use.

I am a health care
provider in the
United States
I am a health care
provider outside
the United States